Literature DB >> 34452583

Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL.

Nicholas A Marston1, Robert P Giugliano1, Jeong-Gun Park1, Andrea Ruzza2, Peter S Sever3, Anthony C Keech4, Marc S Sabatine1.   

Abstract

Entities:  

Keywords:  cholesterol; coronary artery disease; lipids; lipoproteins, LDL; therapeutics

Mesh：

Substances：

Year:  2021        PMID： 34452583      PMCID： PMC8608715          DOI： 10.1161/CIRCULATIONAHA.121.056536

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  5 in total

1.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Scott M Grundy; Neil J Stone; Alison L Bailey; Craig Beam; Kim K Birtcher; Roger S Blumenthal; Lynne T Braun; Sarah de Ferranti; Joseph Faiella-Tommasino; Daniel E Forman; Ronald Goldberg; Paul A Heidenreich; Mark A Hlatky; Daniel W Jones; Donald Lloyd-Jones; Nuria Lopez-Pajares; Chiadi E Ndumele; Carl E Orringer; Carmen A Peralta; Joseph J Saseen; Sidney C Smith; Laurence Sperling; Salim S Virani; Joseph Yeboah
Journal:  Circulation       Date:  2018-11-10       Impact factor: 29.690

2.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Authors:  Marc S Sabatine; Robert P Giugliano; Anthony C Keech; Narimon Honarpour; Stephen D Wiviott; Sabina A Murphy; Julia F Kuder; Huei Wang; Thomas Liu; Scott M Wasserman; Peter S Sever; Terje R Pedersen
Journal:  N Engl J Med       Date:  2017-03-17       Impact factor: 91.245

3.  Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.

Authors:  Robert P Giugliano; Anthony Keech; Sabina A Murphy; Kurt Huber; S Lale Tokgozoglu; Basil S Lewis; Jorge Ferreira; Armando Lira Pineda; Ransi Somaratne; Peter S Sever; Terje R Pedersen; Marc S Sabatine
Journal:  JAMA Cardiol       Date:  2017-12-01       Impact factor: 14.676

4.  Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.

Authors:  Robert P Giugliano; Terje R Pedersen; Jeong-Gun Park; Gaetano M De Ferrari; Zbigniew A Gaciong; Richard Ceska; Kalman Toth; Ioanna Gouni-Berthold; Jose Lopez-Miranda; François Schiele; François Mach; Brian R Ott; Estella Kanevsky; Armando Lira Pineda; Ransi Somaratne; Scott M Wasserman; Anthony C Keech; Peter S Sever; Marc S Sabatine
Journal:  Lancet       Date:  2017-08-28       Impact factor: 79.321

5.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

Authors:  François Mach; Colin Baigent; Alberico L Catapano; Konstantinos C Koskinas; Manuela Casula; Lina Badimon; M John Chapman; Guy G De Backer; Victoria Delgado; Brian A Ference; Ian M Graham; Alison Halliday; Ulf Landmesser; Borislava Mihaylova; Terje R Pedersen; Gabriele Riccardi; Dimitrios J Richter; Marc S Sabatine; Marja-Riitta Taskinen; Lale Tokgozoglu; Olov Wiklund
Journal:  Eur Heart J       Date:  2020-01-01       Impact factor: 29.983
  5 in total
  1 in total

Review 1.  Contemporary Management of Dyslipidemia.

Authors:  Richard A Ferraro; Thorsten Leucker; Seth S Martin; Maciej Banach; Steven R Jones; Peter P Toth
Journal:  Drugs       Date:  2022-03-18       Impact factor: 11.431
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.